https://www.selleckchem.com/pr....oducts/triptolide.ht
In 79 patients treated with combination therapy of ICPI and chemotherapy, the rate of "5% or more within 12 weeks" was significantly different between"TTF≤12 weeks", and "12 weeks
<ttf". however, the only significant favorable factor for ttf was "female gender". in nsclc patients treated with icpi therapy, especially monotherapy, eosinophil measurements during treatment might provide information useful predicting prolonged ttf. preliminary retrospective reports showed that zinc supplementation may decrease mortality covid-19 patient
Like
Comment
Share
